Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey
dc.contributor.author | Beksac, Meral | |
dc.contributor.author | Seval, Guldane Cengiz | |
dc.contributor.author | Paydas, Semra | |
dc.contributor.author | Tuglular, Tulin Firatli | |
dc.contributor.author | Arslan, Onder | |
dc.contributor.author | Goker, Hakan | |
dc.contributor.author | Kaynar, Leylagul | |
dc.contributor.author | Altuntas, Fevzi | |
dc.contributor.author | Atalay, Figen | |
dc.contributor.author | Teke, Havva Uskudar | |
dc.contributor.author | Bolaman, Ali Zahit | |
dc.contributor.author | Pehlivan, Mustafa | |
dc.contributor.author | Sonmez, Mehmet | |
dc.contributor.author | Demir, Ahmet Muzaffer | |
dc.contributor.author | Topcuoglu, Pervin | |
dc.contributor.author | Yilmaz, Mehmet | |
dc.contributor.author | Kabukcu, Sibel Hacioglu | |
dc.contributor.author | Albayrak, Murat | |
dc.contributor.author | Yurttas, Nurgul Ozer | |
dc.contributor.author | Salihoglu, Ayse | |
dc.contributor.author | Cakar, Merih Kizil | |
dc.contributor.author | Gurman, Gunhan | |
dc.date.accessioned | 2020-10-23T08:16:02Z | |
dc.date.available | 2020-10-23T08:16:02Z | |
dc.date.issued | 2019 | |
dc.identifier.endpage | E243 | en_US |
dc.identifier.issn | 2152-2650 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.startpage | E242 | en_US |
dc.identifier.uri | http://hdl.handle.net/11727/4957 | |
dc.identifier.volume | 19 | en_US |
dc.identifier.wos | 000491229800399 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.clml.2019.09.402 | en_US |
dc.relation.journal | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | elotuzumab | en_US |
dc.subject | immunomodulatory drugs | en_US |
dc.subject | Multiple myeloma | en_US |
dc.title | Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey | en_US |
dc.type | conferenceObject | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: